Verify Opioid Treatment Agreement Measure

CmS proposed to reduce two measures to combat the opioid epidemic. CMS on Tuesday reviewed its IT efforts to address the opioid epidemic as part of its proposed annual update for the hospital`s prospective hospital payment system. For at least one patient for whom a List II opioid has been prescribed electronically by the clinician capable of using CEHRT during the performance period, if the total duration of the patient`s schedule II opioid prescriptions is at least 30 cumulative days in a 6-month retrospective period, the MIPS-capable clinician strives to identify the existence of a signed opioid treatment agreement and add it to the patient`s electronic health record record. Below are the certification criteria and standards for electronic medical record technology that support this measure. Number of unambiguous patients for whom a List II opioid has been prescribed electronically by the MIPS-compliant clinician, who uses CEHRT during the performance period, and the total duration of List II opioid prescriptions is at least 30 cumulative days, as reported in the patient`s medical hospital for a period of 6 months retrospective. The quality category data completeness threshold is 70 percent of all patients in all media for claims, electronic clinical quality measures (eCQMs), registration measures and QCDR (Qualified Clinical Data Registry) instead of 60 percent in 2019. In 2019, CMS evaluated the performance of these measures for the cost category; Total Cost Per Capita (TPCC), Medicare Spending Per Beneficiary (MSPB) and 8 episode-based measures. In 2020, CMS will retain the 8 existing episode-based metrics and add 10 new episode-based metrics. CMS has also revised the TPCC and MSPB measurement specifications. The agency, which had previously announced that hospitals should integrate prescription drug monitoring programs into their EHR by 2020, has chosen to continue offering the “PDMP Consultation” measure as an optional bonus position next year. The CMS also proposed to remove the Verify Opioid Treatment Agreement measure for 2020. It is expected to be optional for 2019 and 2020. To achieve this goal and measurement, mips-capable clinicians must use the competencies and standards defined for CEHRT at 45 CFR 170.315 (a) (10) (i), (ii) and (b) (3).

In addition, the Agency is seeking comments on the adoption of two new clinical opioid quality measures for the 2021 reference period: safe use of opioids, simultaneous prescription and hospital harm, opioid-related adverse events. Two new bonuses have been added to the Promoting Interoperability (PI) category in the Merit-Based Incentive Payment System (MIPS) program for 2019. The new measures are not necessary and do not contribute to the Measure Score, but they each contribute to 5 bonus points.